Eli Lilly plans to invest $5.3 billion to increase production of Zepbound and Mounjaro From Investing.com

Eli Lilly plans to invest $5.3 billion to increase production of Zepbound and Mounjaro From Investing.com
Eli Lilly plans to invest $5.3 billion to increase production of Zepbound and Mounjaro From Investing.com

Eli Lilly (LLY) will invest $5.3 billion to expand manufacturing capacity for its high-demand anti-obesity drug Zepbound and its diabetes treatment Mounjaro in response to current undersupplies of these high-demand drugs.

On Friday, the company will disclose its plan to significantly increase the size of a manufacturing facility located on a 600-acre site in Lebanon, Indiana, near its Indianapolis headquarters. Including previous investments, Lilly’s total spending on this new facility will be $9 billion, making it the company’s largest investment to date.

Another pharmaceutical company, Novo Nordisk (NVO), is experiencing similar difficulties in supplying its analog drugs, Ozempic and Wegovy. Both Eli Lilly and Novo Nordisk are dedicating several billion dollars to improve their manufacturing capabilities and meet the growing need for these drugs.

According to market analysts, Zepbound, introduced in late 2023, is currently prescribed more than 74,800 times per week in the United States. The number of Mounjaro weekly prescriptions increased by 48% compared to the previous year, now exceeding 300,000 units.

In November, Novo Nordisk announced plans to invest more than $6 billion to expand its manufacturing facilities in Denmark. Additionally, in February, the company committed to purchasing $11 billion worth of manufacturing facilities from Catalent.

Lilly expects the plant in Lebanon to begin producing drugs by the end of 2026, with the scale of operations expected to grow over the next two years.

The Lebanese site will be equipped to produce tirzepatide, the active compound in Zepbound and Mounjaro, and will be ready to produce other drugs, including potential new anti-obesity treatments that are awaiting clinical trial results and regulatory authorization.

This article was composed and translated with the help of artificial intelligence and has been reviewed by an editor. For further details, please see our Terms and Conditions.

 
For Latest Updates Follow us on Google News
 

PREV Fire Brigade and Carabinieri in action
NEXT “Still no autopsy, there is a risk that the truth will go away”